Q2
7 dage siden
Ordredybde
Antal
Køb
145
Sælg
Antal
265
Seneste handel
| Tid | Pris | Antal | Købere | Sælgere |
|---|---|---|---|---|
| - | - | - | - |
Højest
1,41VWAP
Lavest
1,37OmsætningAntal
0,1 96.280
VWAP
Højest
1,41Lavest
1,37OmsætningAntal
0,1 96.280
Mæglerstatistik
Ingen data fundet
Corporate Actions
| Næste begivenhed | |
|---|---|
Finanskalender er ikke tilgængelig | |
| Tidligere begivenheder | ||
|---|---|---|
| 2025 Q2 | 14. aug. | |
| 2025 Q1 | 14. maj | |
| 2024 Årsregnskab | 28. mar. | |
| 2024 Q3 | 12. nov. 2024 | |
| 2023 Generalforsamling | 12. sep. 2024 |
Data hentes fra Morningstar
Andre har kigget på
Shareville
Deltag i samtalen med SharevilleBliv en del af vores forum for investorer. Følg andre, og diskuter aktier og fonde.
Log ind
7. mar.7. mar.According to March 4, 2025 information, the first two-part human study with Ketamir-2 is ready to start: https://finance.yahoo.com/news/mira-pharmaceuticals-announces-approval-initiation-130000869.html . According to ACCESS Newswire, ”This Phase 1, randomized, double-blind, placebo-controlled, single-center study is designed to evaluate the safety, tolerability, and pharmacokinetics of orally administered Ketamir-2 in healthy adult volunteers… …The Company expects Phase 1 to conclude by Q4 2025, paving the way for a Phase 2a study in neuropathic pain patients to be initiated by the end of the year.” The stock price has been low, again. So, I have taken it into account by increasing my share. I presume that the road during this year is going to be rocky, but the first human results are not so far away.- 7. jan.7. jan.The stock price of MIRA Pharmaceuticals (MIRA) is up well more than 10 per cents today when writing this text. MIRA is a drug company without any drugs to sell. So, it is in the preclinical phase. Why is the price moving heavily down and upwards? MIRA has studied a drug (ketamine), which is nowadays given intravenously for patients with difficult neuropathic pain. However, MIRAs Ketamir-2 is a new ketamine analog, which can be administered orally. No needles or whatsoever! The basic studies and studies with mice have been succesful. Just in December 2024 MIRA has submitted an Investigational New Drug application to the U.S. Food and Drug Administration (FDA) for Ketamir-2 for the treatment of neuropathic pain. The 1st phase human studies are planned to begin during Q1/2025. The US-Europe (Netherland) cooperation to complete these studies is on its way. It is possible, that MIRA might need more money before it gets the first drug to the market. However, if the first human studies will be succesful, cooperation with big drug company/-ies becomes very possible. The market of neuropathic pain is very large and it is increasing continuously. To summarise, MIRA is a risky investment but it has a big, big potential to become a winner. The start of the very first human study is near. It is interesting to follow the company and to be with it as a private investor, who follows carefully how the stock price fluctuates in the near future.
7. jan.7. jan.Jeg kjøpte disse for å ikke så lenge siden, men ombestemte meg fordi den er svær volatil. Men verdt å følge selskapet som du sier:)
Kommentarerne ovenfor kommer fra Nordnets sociale netværk Shareville og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.
Nyheder og Analyser
Der er i øjeblikket ingen nyheder
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Q2
7 dage siden
Nyheder og Analyser
Der er i øjeblikket ingen nyheder
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Shareville
Deltag i samtalen med SharevilleBliv en del af vores forum for investorer. Følg andre, og diskuter aktier og fonde.
Log ind
- 7. mar.7. mar.According to March 4, 2025 information, the first two-part human study with Ketamir-2 is ready to start: https://finance.yahoo.com/news/mira-pharmaceuticals-announces-approval-initiation-130000869.html . According to ACCESS Newswire, ”This Phase 1, randomized, double-blind, placebo-controlled, single-center study is designed to evaluate the safety, tolerability, and pharmacokinetics of orally administered Ketamir-2 in healthy adult volunteers… …The Company expects Phase 1 to conclude by Q4 2025, paving the way for a Phase 2a study in neuropathic pain patients to be initiated by the end of the year.” The stock price has been low, again. So, I have taken it into account by increasing my share. I presume that the road during this year is going to be rocky, but the first human results are not so far away.
- 7. jan.7. jan.The stock price of MIRA Pharmaceuticals (MIRA) is up well more than 10 per cents today when writing this text. MIRA is a drug company without any drugs to sell. So, it is in the preclinical phase. Why is the price moving heavily down and upwards? MIRA has studied a drug (ketamine), which is nowadays given intravenously for patients with difficult neuropathic pain. However, MIRAs Ketamir-2 is a new ketamine analog, which can be administered orally. No needles or whatsoever! The basic studies and studies with mice have been succesful. Just in December 2024 MIRA has submitted an Investigational New Drug application to the U.S. Food and Drug Administration (FDA) for Ketamir-2 for the treatment of neuropathic pain. The 1st phase human studies are planned to begin during Q1/2025. The US-Europe (Netherland) cooperation to complete these studies is on its way. It is possible, that MIRA might need more money before it gets the first drug to the market. However, if the first human studies will be succesful, cooperation with big drug company/-ies becomes very possible. The market of neuropathic pain is very large and it is increasing continuously. To summarise, MIRA is a risky investment but it has a big, big potential to become a winner. The start of the very first human study is near. It is interesting to follow the company and to be with it as a private investor, who follows carefully how the stock price fluctuates in the near future.7. jan.7. jan.Jeg kjøpte disse for å ikke så lenge siden, men ombestemte meg fordi den er svær volatil. Men verdt å følge selskapet som du sier:)
Kommentarerne ovenfor kommer fra Nordnets sociale netværk Shareville og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.
Ordredybde
Antal
Køb
145
Sælg
Antal
265
Seneste handel
| Tid | Pris | Antal | Købere | Sælgere |
|---|---|---|---|---|
| - | - | - | - |
Højest
1,41VWAP
Lavest
1,37OmsætningAntal
0,1 96.280
VWAP
Højest
1,41Lavest
1,37OmsætningAntal
0,1 96.280
Mæglerstatistik
Ingen data fundet
Andre har kigget på
Corporate Actions
| Næste begivenhed | |
|---|---|
Finanskalender er ikke tilgængelig | |
| Tidligere begivenheder | ||
|---|---|---|
| 2025 Q2 | 14. aug. | |
| 2025 Q1 | 14. maj | |
| 2024 Årsregnskab | 28. mar. | |
| 2024 Q3 | 12. nov. 2024 | |
| 2023 Generalforsamling | 12. sep. 2024 |
Data hentes fra Morningstar
Q2
7 dage siden
Nyheder og Analyser
Der er i øjeblikket ingen nyheder
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Corporate Actions
| Næste begivenhed | |
|---|---|
Finanskalender er ikke tilgængelig | |
| Tidligere begivenheder | ||
|---|---|---|
| 2025 Q2 | 14. aug. | |
| 2025 Q1 | 14. maj | |
| 2024 Årsregnskab | 28. mar. | |
| 2024 Q3 | 12. nov. 2024 | |
| 2023 Generalforsamling | 12. sep. 2024 |
Data hentes fra Morningstar
Shareville
Deltag i samtalen med SharevilleBliv en del af vores forum for investorer. Følg andre, og diskuter aktier og fonde.
Log ind
- 7. mar.7. mar.According to March 4, 2025 information, the first two-part human study with Ketamir-2 is ready to start: https://finance.yahoo.com/news/mira-pharmaceuticals-announces-approval-initiation-130000869.html . According to ACCESS Newswire, ”This Phase 1, randomized, double-blind, placebo-controlled, single-center study is designed to evaluate the safety, tolerability, and pharmacokinetics of orally administered Ketamir-2 in healthy adult volunteers… …The Company expects Phase 1 to conclude by Q4 2025, paving the way for a Phase 2a study in neuropathic pain patients to be initiated by the end of the year.” The stock price has been low, again. So, I have taken it into account by increasing my share. I presume that the road during this year is going to be rocky, but the first human results are not so far away.
- 7. jan.7. jan.The stock price of MIRA Pharmaceuticals (MIRA) is up well more than 10 per cents today when writing this text. MIRA is a drug company without any drugs to sell. So, it is in the preclinical phase. Why is the price moving heavily down and upwards? MIRA has studied a drug (ketamine), which is nowadays given intravenously for patients with difficult neuropathic pain. However, MIRAs Ketamir-2 is a new ketamine analog, which can be administered orally. No needles or whatsoever! The basic studies and studies with mice have been succesful. Just in December 2024 MIRA has submitted an Investigational New Drug application to the U.S. Food and Drug Administration (FDA) for Ketamir-2 for the treatment of neuropathic pain. The 1st phase human studies are planned to begin during Q1/2025. The US-Europe (Netherland) cooperation to complete these studies is on its way. It is possible, that MIRA might need more money before it gets the first drug to the market. However, if the first human studies will be succesful, cooperation with big drug company/-ies becomes very possible. The market of neuropathic pain is very large and it is increasing continuously. To summarise, MIRA is a risky investment but it has a big, big potential to become a winner. The start of the very first human study is near. It is interesting to follow the company and to be with it as a private investor, who follows carefully how the stock price fluctuates in the near future.7. jan.7. jan.Jeg kjøpte disse for å ikke så lenge siden, men ombestemte meg fordi den er svær volatil. Men verdt å følge selskapet som du sier:)
Kommentarerne ovenfor kommer fra Nordnets sociale netværk Shareville og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.
Ordredybde
Antal
Køb
145
Sælg
Antal
265
Seneste handel
| Tid | Pris | Antal | Købere | Sælgere |
|---|---|---|---|---|
| - | - | - | - |
Højest
1,41VWAP
Lavest
1,37OmsætningAntal
0,1 96.280
VWAP
Højest
1,41Lavest
1,37OmsætningAntal
0,1 96.280
Mæglerstatistik
Ingen data fundet